Single-nucleotide polymorphism mutation spectra and resistance to quinolones in Salmonella enterica serovar Enteritidis with a mutator phenotype.
Resistance to quinolone antibiotics has been associated with single-nucleotide polymorphisms (SNPs) in the quinolone resistance-determining region (QRDR) of gyrA. Mutations in the gyrA gene were compared by using mutant populations derived from wild-type Salmonella enterica serovar Enteritidis and its isogenic mutS::Tn10 mutator counterpart. Spontaneous mutants arising during nonselective growth were isolated by selection with either nalidixic acid, enrofloxacin, or ciprofloxacin. QRDR SNPs were identified in approximately 70% (512 of 695) of the isolates via colony hybridization with radiolabeled oligonucleotide probes. Notably, transition base substitution SNPs in the QRDR were dramatically increased in mutants derived from the mutS strain. Some, but not all, antibiotic-resistant mutants lacking QRDR SNPs were resistant to tetracycline and chloramphenicol, consistent with alterations in nonspecific efflux pumps or other membrane transport mechanisms. Changing the selection conditions shifted the mutation spectrum. Selection with ciprofloxacin was least likely to yield a mutant harboring either a QRDR SNP or chloramphenicol resistance. Selection with enrofloxacin was more likely to yield mutants containing Ser83-->Phe mutations, whereas selection with ciprofloxacin or nalidixic acid favored recovery of Asp87-->Gly mutants. Fluoroquinolone-resistant Salmonella strains isolated from veterinary or clinical settings frequently display a mutational spectrum with a preponderance of transition SNPs in the QRDR, the pattern found in vitro among mutS mutator mutants reported here. Both the preponderance of transition mutations and the varied mutation spectra reported for veterinary and clinical isolates suggest that bacterial mutators defective in methyl-directed mismatch repair may play a role in the emergence of quinolone and fluoroquinolone resistance in feral settings.
Levy
Dan D
DD
Division of Molecular Biology, Center for Food Safety & Nutrition, U.S. Food and Drug Administration, HFS-025, 8301 Muirkirk Road, Laurel, MD 20708, USA.
Sharma
Bhavana
B
Cebula
Thomas A
TA
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D020137:Base Pair Mismatch / Q000235:genetics; D002701:Chloramphenicol / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D027081:DNA Gyrase / Q000235:genetics; D017931:DNA Primers; D015342:DNA Probes; D004260:DNA Repair / Q000235:genetics; D027101:DNA Topoisomerase IV / Q000235:genetics; D024881:Drug Resistance, Bacterial; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics*; D009268:Nalidixic Acid / Q000494:pharmacology; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D015363:Quinolones / Q000494:pharmacology*; D012480:Salmonella Infections / Q000382:microbiology*; D019779:Salmonella enterica / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D017931:DNA Primers; D015342:DNA Probes; D024841:Fluoroquinolones; D015363:Quinolones; D009268:Nalidixic Acid; D000077422:Enrofloxacin; D002939:Ciprofloxacin; D002701:Chloramphenicol; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase